Skip to main content
Study evaluates glibenclamide oral suspension in neonatal diabetes
2/4/2019

French researchers found that children with neonatal diabetes who were given glibenclamide oral suspension after initial dosage of glibenclamide tablets had similar HbA1C and incidence of hypoglycemia or hyperglycemia after four months than at baseline. The findings in Pediatric Diabetes also showed that the oral suspension therapy was preferred by younger children, while tablets were preferred by those who were older.

Full Story: